Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment
(1) Background: The importance of total eosinophil count in peripheral blood (EOS) as a type 2 inflammation marker is known to be fundamental in asthma, chronic sinusitis, and vasculitis. In cancer, despite their questionable antiproliferative effect, their role remains unclear. Our purpose was to d...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/11/2596 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846154169094766592 |
|---|---|
| author | Wojciech Ciesielski Izabela Kupryś-Lipińska Anna Kumor-Kisielewska Oliwia Grząsiak Julia Borodacz Sebastian Niedźwiecki Piotr Hogendorf Adam Durczyński Janusz Strzelczyk Alicja Majos |
| author_facet | Wojciech Ciesielski Izabela Kupryś-Lipińska Anna Kumor-Kisielewska Oliwia Grząsiak Julia Borodacz Sebastian Niedźwiecki Piotr Hogendorf Adam Durczyński Janusz Strzelczyk Alicja Majos |
| author_sort | Wojciech Ciesielski |
| collection | DOAJ |
| description | (1) Background: The importance of total eosinophil count in peripheral blood (EOS) as a type 2 inflammation marker is known to be fundamental in asthma, chronic sinusitis, and vasculitis. In cancer, despite their questionable antiproliferative effect, their role remains unclear. Our purpose was to describe the relationship between baseline blood EOS and overall survival (OS) in pancreatic ductal adenocarcinoma (PDAC) patients. (2) Methods: We retrospectively analyzed data from 137 adult patients who underwent surgical treatment for pancreatic ductal adenocarcinoma (PDAC) between the years 2012 and 2019. Patients with no recent history of systemic steroid use and without intraoperative metastases were included. Patients were categorized into two groups based on EOS (≥0.1 G/l and <0.1 G/l). Survival outcomes were analyzed using Cox proportional hazards regression models. (3) Results: According to EOS and PDAC stage, median OS values were as follows: in stage I–III, EOS ≥ 0.1 G/l group: 14.5 months, in stage I–III, EOS < 0.1 G/l group: 8.0 months, in stage IV, EOS ≥ 0.1 G/l group: 7.0 months, and in stage IV, EOS < 0.1 G/l group: 5.0 months. EOS < 0.1 G/l (vs. ≥0.1 G/l) was an independent prognostic factor for OS in both the uni- and multivariate Cox regression, respectively (HR = 1.48, <i>p</i> = 0.035 and HR = 1.57, <i>p</i> = 0.021). (4) Conclusions: Peripheral eosinophilia seems to be a potential independent prognostic factor. Further studies are necessary to confirm this hypothesis, since our findings suggest that type 2 inflammation may be the factor directly or indirectly lengthening the survival of patients with PDAC. |
| format | Article |
| id | doaj-art-535cc28c313a47b28d6c8652f68672e4 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-535cc28c313a47b28d6c8652f68672e42024-11-26T17:53:22ZengMDPI AGBiomedicines2227-90592024-11-011211259610.3390/biomedicines12112596Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical TreatmentWojciech Ciesielski0Izabela Kupryś-Lipińska1Anna Kumor-Kisielewska2Oliwia Grząsiak3Julia Borodacz4Sebastian Niedźwiecki5Piotr Hogendorf6Adam Durczyński7Janusz Strzelczyk8Alicja Majos9General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, PolandInternal Medicine, Asthma and Allergy Department, Medical University of Łódź, 90-419 Łódź, PolandDepartment of Pneumology and Allergy, Medical University of Łódź, 90-419 Łódź, PolandGeneral and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, PolandStudents’ Scientific Association in General and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, PolandDepartment of Surgical Oncology, Medical University of Łódź, 90-419 Łódź, PolandGeneral and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, PolandGeneral and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, PolandGeneral and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, PolandGeneral and Transplant Surgery Department, Medical University of Łódź, 90-419 Łódź, Poland(1) Background: The importance of total eosinophil count in peripheral blood (EOS) as a type 2 inflammation marker is known to be fundamental in asthma, chronic sinusitis, and vasculitis. In cancer, despite their questionable antiproliferative effect, their role remains unclear. Our purpose was to describe the relationship between baseline blood EOS and overall survival (OS) in pancreatic ductal adenocarcinoma (PDAC) patients. (2) Methods: We retrospectively analyzed data from 137 adult patients who underwent surgical treatment for pancreatic ductal adenocarcinoma (PDAC) between the years 2012 and 2019. Patients with no recent history of systemic steroid use and without intraoperative metastases were included. Patients were categorized into two groups based on EOS (≥0.1 G/l and <0.1 G/l). Survival outcomes were analyzed using Cox proportional hazards regression models. (3) Results: According to EOS and PDAC stage, median OS values were as follows: in stage I–III, EOS ≥ 0.1 G/l group: 14.5 months, in stage I–III, EOS < 0.1 G/l group: 8.0 months, in stage IV, EOS ≥ 0.1 G/l group: 7.0 months, and in stage IV, EOS < 0.1 G/l group: 5.0 months. EOS < 0.1 G/l (vs. ≥0.1 G/l) was an independent prognostic factor for OS in both the uni- and multivariate Cox regression, respectively (HR = 1.48, <i>p</i> = 0.035 and HR = 1.57, <i>p</i> = 0.021). (4) Conclusions: Peripheral eosinophilia seems to be a potential independent prognostic factor. Further studies are necessary to confirm this hypothesis, since our findings suggest that type 2 inflammation may be the factor directly or indirectly lengthening the survival of patients with PDAC.https://www.mdpi.com/2227-9059/12/11/2596cancer biologyclinical observationsimmunologypancreatic ductal adenocarcinomapancreatic cancer |
| spellingShingle | Wojciech Ciesielski Izabela Kupryś-Lipińska Anna Kumor-Kisielewska Oliwia Grząsiak Julia Borodacz Sebastian Niedźwiecki Piotr Hogendorf Adam Durczyński Janusz Strzelczyk Alicja Majos Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment Biomedicines cancer biology clinical observations immunology pancreatic ductal adenocarcinoma pancreatic cancer |
| title | Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment |
| title_full | Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment |
| title_fullStr | Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment |
| title_full_unstemmed | Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment |
| title_short | Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment |
| title_sort | peripheral eosinophil count may be the prognostic factor for overall survival in patients with pancreatic ductal adenocarcinoma undergoing surgical treatment |
| topic | cancer biology clinical observations immunology pancreatic ductal adenocarcinoma pancreatic cancer |
| url | https://www.mdpi.com/2227-9059/12/11/2596 |
| work_keys_str_mv | AT wojciechciesielski peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT izabelakupryslipinska peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT annakumorkisielewska peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT oliwiagrzasiak peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT juliaborodacz peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT sebastianniedzwiecki peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT piotrhogendorf peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT adamdurczynski peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT januszstrzelczyk peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment AT alicjamajos peripheraleosinophilcountmaybetheprognosticfactorforoverallsurvivalinpatientswithpancreaticductaladenocarcinomaundergoingsurgicaltreatment |